INDGN.NS Profit & Loss
Indegene Ltd.
Profit & Loss Balance Sheet Cash Flow
Profit & Loss · 3 years on file
(FY2023-24 to FY2025-26)
· fetched 2026-08-24 01:38
| Line item | FY2023-24 | FY2024-25 | FY2025-26 | Source (XBRL element) |
|---|---|---|---|---|
| Revenue from Operations | ₹2,589.60 Cr. | ₹2,839.30 Cr. | ₹3,510.50 Cr. | RevenueFromOperations |
| Gross Revenue (incl. inter-segment) | ₹2,589.60 Cr. | ₹2,839.30 Cr. | ₹3,510.50 Cr. | SegmentRevenueFromOperations |
| Other Income | ₹76.30 Cr. | ₹107.20 Cr. | ₹72.00 Cr. | OtherIncome |
| Total Income | ₹2,665.90 Cr. | ₹2,946.50 Cr. | ₹3,582.50 Cr. | Income |
| Cost of Materials Consumed | ₹0.00 Cr. | ₹0.00 Cr. | ₹0.00 Cr. | CostOfMaterialsConsumed |
| Purchases of Stock-in-Trade | ₹0.00 Cr. | ₹0.00 Cr. | ₹0.00 Cr. | PurchasesOfStockInTrade |
| Changes in Inventories | ₹0.00 Cr. | ₹0.00 Cr. | ₹0.00 Cr. | ChangesInInventoriesOfFinishedGoodsWorkInProgressAndStockInTrade |
| Employee Benefit Expense | ₹1,651.60 Cr. | ₹1,815.20 Cr. | ₹2,197.70 Cr. | EmployeeBenefitExpense |
| Finance Costs | ₹49.40 Cr. | ₹22.00 Cr. | ₹19.30 Cr. | FinanceCosts |
| Depreciation and Amortisation | ₹76.10 Cr. | ₹80.20 Cr. | ₹126.40 Cr. | DepreciationDepletionAndAmortisationExpense |
| Other Expenses | ₹432.60 Cr. | ₹489.80 Cr. | ₹693.80 Cr. | OtherExpenses |
| Total Expenses | ₹2,209.70 Cr. | ₹2,407.20 Cr. | ₹3,037.20 Cr. | Expenses |
| Profit Before Exceptional Items and Tax | ₹456.20 Cr. | ₹539.30 Cr. | ₹545.30 Cr. | ProfitBeforeExceptionalItemsAndTax |
| Exceptional Items | ₹2.40 Cr. | ₹0.00 Cr. | ₹-20.30 Cr. | ExceptionalItemsBeforeTax |
| Profit Before Tax | ₹458.60 Cr. | ₹539.30 Cr. | ₹525.00 Cr. | ProfitBeforeTax |
| Tax Expense | ₹121.90 Cr. | ₹132.60 Cr. | ₹123.90 Cr. | TaxExpense |
| Net Profit (incl. minority interest) | ₹336.70 Cr. | ₹406.70 Cr. | ₹401.10 Cr. | ProfitLossForPeriod |
| Net Profit (to shareholders) | ₹344.60 Cr. | N/A | ₹401.10 Cr. | ProfitOrLossAttributableToOwnersOfParent |
| Basic EPS | ₹15.19 | ₹17.15 | ₹16.72 | BasicEarningsLossPerShareFromContinuingAndDiscontinuedOperations |
| Diluted EPS | ₹15.07 | ₹17.02 | ₹16.62 | DilutedEarningsLossPerShareFromContinuingAndDiscontinuedOperations |
Every figure above is the exact value of the named XBRL element from INDGN.NS's cached filing for that year — nothing here is estimated or backfilled. A company shows one column per year StockProof actually has data for — never padded with blank years. Rows shown as N/A are genuinely not disclosed under that year's filing format (see peer comparison for how other Healthcare companies compare).